Top 10 Gene & Cell Therapy Companies

Kite Pharma, a wholly owned subsidiary of Gilead Sciences, is the undisputed global leader in CAR-T cell therapy commercialization. Its flagship product Yescarta generated $1.5 billion in 2025 revenue, while Tecartus contributed $344 million. Kite operates four wholly-owned GMP-certified cell therapy manufacturing facilities across the United States and Europe, achieving a remarkable 14-day vein-to-vein turnaround time.

Strengths: Largest dedicated CAR-T manufacturing infrastructure worldwide; FDA removal of REMS requirements …

Novartis has executed the pharmaceutical industry's most distinctive manufacturing transformation—shedding the high-volume, low-complexity generics production of Sandoz to concentrate its 33 global manufacturing sites entirely on advanced therapeutic platforms where production complexity creates durable competitive moats. The company's FY2025 net sales reached $54.5 billion, driven by core innovative medicines including Cosentyx ($4.5 billion in immunology), Entresto ($3.5 billion in cardiovascular), and a rapidly growing radiopharmaceutical franchise. Novartis's strategic …

Bristol-Myers Squibb has built a focused, high-value biopharmaceutical manufacturing network centered on immuno-oncology, hematology, and cardiovascular production, generating approximately $46.8 billion in FY2025 revenue across 12 owned manufacturing facilities. The company's manufacturing operations are organized around its three therapeutic franchises: oncology—producing the PD-1 inhibitor Opdivo (nivolumab) through large-scale CHO cell culture and multi-column chromatography purification, CAR-T cell therapies Breyanzi and Abecma through patient-specific autologous cell …

Legend Biotech has emerged as one of the most successful cell therapy companies globally, with its BCMA-targeted CAR-T therapy CARVYKTI achieving approximately $1.9 billion in global end-user sales during 2025. The company recorded $627 million in recognized revenue and has treated over 10,000 patients across 18 markets worldwide. A collaboration with Johnson & Johnson has enabled rapid global commercial expansion and manufacturing capacity buildout.

Strengths: CARVYKTI's exceptional clinical data with high complete response rates; Read More

Sarepta Therapeutics is the global leader in gene therapy and RNA-targeted therapeutics for rare neuromuscular diseases, generating $1.86 billion in net product revenue during 2025. Its Duchenne muscular dystrophy (DMD) gene therapy ELEVIDYS achieved $899 million in sales, while its PMO-based RNA therapies contributed $966 million. The company's strategic restructuring, including a 36% workforce reduction, has positioned it for sustained cash flow generation.

Strengths: Unique dual-platform approach covering both gene therapy (AAV) an…

Vertex Pharmaceuticals has established itself as a pioneer in CRISPR-based gene editing through its groundbreaking therapy CASGEVY, the first ever approved CRISPR/Cas9 gene-edited cell therapy. During 2025, Vertex generated approximately $120 billion total revenue while CASGEVY contributed $116 million. The product achieved 90% insurance coverage in the US and expanded to 12 countries, treating patients with sickle cell disease and transfusion-dependent beta-thalassemia.

Strengths: Pioneering first-in-class CRISPR gene-edited therapy …

Lonza Group is the world's largest contract development and manufacturing organization (CDMO), serving as the foundational manufacturing partner for the global CGT industry. In 2025, Lonza generated 6.53 billion Swiss francs ($7.4 billion) in revenue with a 31.6% EBITDA margin. The company scored a landmark achievement by winning the commercial manufacturing contract for CASGEVY at its Geleen, Netherlands facility, the first factory approved across FDA, EMA, and MHRA for CRISPR therapy production.

Strengths: Unmatched global manufacturing infr…

Thermo Fisher Scientific Inc. is the world's leading provider of scientific services, headquartered in Waltham, Massachusetts, USA. Through its four business segments—Life Sciences, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Services—it delivers comprehensive workflow solutions from basic research to clinical application for global pharmaceutical and biotech companies, research institutions, and clinical labs. With revenue of approximately US$50 billion in FY2025, Thermo Fisher has become an infrastructural partner underpinning innovation in the global life sci…

Minaris Advanced Therapies emerged in 2025 as a transformative new entity in the CGT CDMO landscape, formed through the strategic merger of Altaris-owned Minaris Regenerative Medicine and the acquired WuXi Advanced Therapies (formerly WuXi ATU) manufacturing assets. This combination creates a uniquely positioned, geopolitically de-risked CGT manufacturing powerhouse with facilities across the US, UK, and Japan. The merger was driven by the BIOSECURE Act and growing demand for supply chain diversification away from China-headquartered providers.

Strengths:Read More

GenScript Biotech has established itself as a dominant force in the gene synthesis and CGT CDMO market, achieving $959.5 million in 2025 revenue with extraordinary 61.4% year-over-year growth. Its ProBio CDMO subsidiary experienced explosive 309.1% revenue growth to $388.7 million, driven by surging demand for plasmid DNA, viral vector manufacturing, and gene synthesis services. GenScript's unique ecosystem approach, encompassing parent company gene synthesis, ProBio CDMO, and Legend Biotech (cell therapy), creates an integrated CGT value chain.

Strengths:Read More